SAC Capital Advisors’s Novo Nordisk NVO Stock Holding History

SAC Capital Advisors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-19,924	Closed	-$455K	–	700
2014 Q1	$455K	Sell	19,924 -11,486	-37%	-$245K	﹤0.01%	1229
2013 Q4	$580K	Sell	31,410 -29,610	-49%	-$516K	﹤0.01%	1109
2013 Q3	$1.03M	Buy	61,020 +17,940	+42%	+$302K	0.01%	926
2013 Q2	$668K	Buy	+43,080	New	+$717K	﹤0.01%	1006

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

MAA

Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return

SAC Capital Advisors's NVO Position: Q2 2014 in Review

SAC Capital Advisors sold out of Novo Nordisk (NVO) in Q2 2014, closing a stake of 19,924 shares — an estimated $455K sold.

SAC Capital Advisors first reported a position in NVO in Q2 2013 and held it in 4 quarters. The position peaked at $1.03M in Q3 2013. 473 funds tracked by Wall St. Rank hold NVO as of Q2 2014.

SAC Capital Advisors reported no remaining Novo Nordisk position as of Q2 2014 after selling out during the quarter.
SAC Capital Advisors sold 19,924 Novo Nordisk shares in Q2 2014, an estimated $455K.
SAC Capital Advisors first reported a position in Novo Nordisk in Q2 2013 and held it in 4 quarters.
SAC Capital Advisors's Novo Nordisk position peaked at $1.03M in Q3 2013.
473 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.